The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

xenotx.org

Founded Year

2016

Stage

Unattributed | Alive

Total Raised

$700K

Last Raised

$700K | 3 yrs ago

About XenoTherapeutics

XenoTherapeutics is a medical device company whose product XenoSkin is a human tissue substitute is derived from genetically modified pigs and serves as a new solution for burn injuries.

XenoTherapeutics Headquarter Location

359 Newbury St

Boston, Massachusetts, 02115,

United States

617-939-7892

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing XenoTherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

XenoTherapeutics is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,395 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

XenoTherapeutics Patents

XenoTherapeutics has filed 10 patents.

The 3 most popular patent topics include:

  • Transplantation medicine
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/22/2021

10/26/2021

Immunology, Transcription factors, Immune system, Clusters of differentiation, Transplantation medicine

Grant

Application Date

4/22/2021

Grant Date

10/26/2021

Title

Related Topics

Immunology, Transcription factors, Immune system, Clusters of differentiation, Transplantation medicine

Status

Grant

Latest XenoTherapeutics News

From Pig to Patient: XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant; Evidence of Safety and Efficacy Allows for Accelerated Patient Enrollment

Nov 7, 2020

From Pig to Patient: XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant; Evidence of Safety and Efficacy Allows for Accelerated Patient Enrollment From Pig to Patient: XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant; Evidence of Safety and Efficacy Allows for Accelerated Patient Enrollment Share Last updated Nov 5, 2020 BOSTON, MA, Nov. 05, 2020 (GLOBE NEWSWIRE) — XenoTherapeutics, a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs, has completed the first of two patient cohorts in the company’s Phase I clinical trial of Xeno-Skin™, a first-in-human, live-cell xenotransplant for the treatment of severe and extensive burn wounds. As a result, the U.S. Food and Drug Administration (FDA) has agreed to permit accelerated patient enrollment; patients may now enroll in the trial’s second cohort simultaneously. This first-in-human trial, conducted in partnership with the Massachusetts General Hospital, is expected to be completed by the end of 2020. More information is available at clinicaltrials.gov . “As an engineer and scientist, I’m trained to be skeptical and rely heavily on real data, and to prioritize facts above what we hope to see as a company. In this case, the evidence speaks for itself – there’s no doubt this works. Combine these results with our understanding of essential regulatory requirements specifically related to xenotransplantation, and our demonstrated capability in clinical grade manufacturing of xenotransplantation products, this seemingly small step has significant positive implications for patient care, for our field, and where we’re headed,” said XenoTherapeutics Corporation CEO Paul Holzer. “This affirms my enthusiasm for where our discoveries will go from here – very big things are coming soon.” Surgeries to implant Xeno-Skin™ were performed under the care of Dr. Jeremy Goverman (Principal Investigator) and Dr. John Schulz at the Massachusetts General Hospital (MGH) Sumner Redstone Burn Center. All patients who participated in the trial received surgical transplants of both live skin from a clinical-grade, genetically engineered porcine donor …

  • When was XenoTherapeutics founded?

    XenoTherapeutics was founded in 2016.

  • Where is XenoTherapeutics's headquarters?

    XenoTherapeutics's headquarters is located at 359 Newbury St, Boston.

  • What is XenoTherapeutics's latest funding round?

    XenoTherapeutics's latest funding round is Unattributed.

  • How much did XenoTherapeutics raise?

    XenoTherapeutics raised a total of $700K.

  • Who are the investors of XenoTherapeutics?

    Investors of XenoTherapeutics include MassChallenge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.